Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunochemotherapy for Recurrent Esophageal Squamous Cell Carcinoma
NCT07016737Phase 3Enrolling by invitation
- Start
- Aug 2024
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC). Started Aug 2024; status: enrolling by invitation.
02
Drugs
sintilimabcamrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07016737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07016737.